{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:24:12Z","timestamp":1761060252996},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3 Part 1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.juro.2016.12.024","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T22:30:54Z","timestamp":1481927454000},"page":"538-540","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bacillus Calmette-Gu\u00e9rin Manufacturing and SWOG S1602 Intergroup Clinical Trial"],"prefix":"10.1097","volume":"197","author":[{"given":"Joshua J.","family":"Meeks","sequence":"first","affiliation":[{"name":"Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[{"name":"Department of Urology, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[{"name":"Department of Urology, UT Health San Antonio, San Antonio, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2016.12.024_bib1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.juro.2016.12.024_bib2","doi-asserted-by":"crossref","first-page":"15443","DOI":"10.1038\/srep15443","article-title":"Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations","volume":"5","author":"Abdallah","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.juro.2016.12.024_bib3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","article-title":"Comparative genomics of BCG vaccines by whole-genome DNA microarray","volume":"284","author":"Behr","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.juro.2016.12.024_bib4","doi-asserted-by":"crossref","first-page":"e71243","DOI":"10.1371\/journal.pone.0071243","article-title":"Genome sequencing and analysis of BCG vaccine strains","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.juro.2016.12.024_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1574-6976.2008.00118.x","article-title":"Influence of BCG vaccine strain on the immune response and protection against tuberculosis","volume":"32","author":"Ritz","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.juro.2016.12.024_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.eururo.2014.06.006","article-title":"Variations between bacillus Calmette-Guerin strains: lessons from tuberculosis prevention","volume":"66","author":"Abate","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.024_bib7","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/j.juro.2016.02.2876","article-title":"A network meta-analysis of intravesical BCG substrain efficacy in the treatment of non-muscle invasive bladder cancer","volume":"195","author":"Boehm","year":"2016","journal-title":"J Urol, suppl"},{"key":"10.1016\/j.juro.2016.12.024_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.024_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.024_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The\u00a0efficacy of BCG TICE and BCG Connaught in\u00a0a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.12.024_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a Southwest Oncology Group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.12.024_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2016.12.024_bib13","first-page":"47","article-title":"Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.juro.2016.12.024_bib14","series-title":"Administration USFD","article-title":"Warning Letter","author":"Malarkey","year":"2012"},{"key":"10.1016\/j.juro.2016.12.024_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer\u2014therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.juro.2016.12.024_bib16","first-page":"192","article-title":"The treatment of Ta-T1 bladder cancer in the era of worldwide BCG shortage","volume":"68","author":"Brausi","year":"2016","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.juro.2016.12.024_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.024_bib18","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.juro.2016.12.024_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716319565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716319565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2016.12.024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:36:37Z","timestamp":1651206997000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2016.12.024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":19,"journal-issue":{"issue":"3 Part 1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1016\/j.juro.2016.12.024"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2016.12.024","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Gu\u00e9rin Manufacturing and SWOG S1602 Intergroup Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2016.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}